MarginsXMarginsX
Home › Markets › Health Care › ADRX

ADARx Pharmaceuticals Inc. (ADRX)

ADRX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$14.00
-1.41% on the day
Market cap
$1.6B
Small cap
Revenue
New registrant: no annual report filed under this company yet
Net income
New registrant: no annual report filed under this company yet

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerADRX on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2026
SEC CIK0001802369
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials

New registrant: no annual report filed under this company yet.

Warning signs

Cash runway
not enough data
$570.6M cash at September 30, 2026
Share count, 1 year
No year-earlier count
Going-concern doubt
No
10-Q filed November 12, 2026
Insider net buying, 12 months
$33.3M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-12
Cash and burn$570.6M cash.Report 2026-09-30
Shares outstanding111,193,446 (2026-11-06).Cover page 2026-11-06
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, San Diego, California, United StatesPCAOB Form AP 2026-09-28
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $33.3M, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$2.2M-$28.1MNot filed$570.6M$815KNeeds four quarters10-Q 2026-11-12
Q3 2026
2026-06-30
Not filed-$25.8MNot filedNot filedNo debt tagsNeeds four quarters10-Q 2026-11-12
Q3 2026
2026-03-31
Not filed-$22.7MNot filedNot filedNo debt tagsNeeds four quarters10-Q 2026-11-12
Q3 2026
2025-09-30
$1.6M-$17.9MNot filed$59.2MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q3 2026
2025-06-30
Not filed-$18.1MNot filedNot filedNo debt tagsNeeds four quarters10-Q 2026-11-12
Q3 2026
2025-03-31
Not filed-$15.6MNot filedNot filedNo debt tagsNeeds four quarters10-Q 2026-11-12

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B42026-09-28
Latest quarterly / interim10-Q2026-11-12
Latest current report8-K2026-11-12

Source: SEC EDGAR submissions feed, 51 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+7.3%
1 month-19.8%
3 monthsNot enough price history
Year to dateNot enough price history
1 yearNot enough price history
From 52-week high-31.2%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
PGENPrecigen Inc.$4.30-5.29%$1.5B
QUREuniQure N.V.$21.88-8.11%$1.5B
SLSSELLAS Life Sciences Group Inc.$7.47-4.96%$1.5B
NRIXNurix Therapeutics Inc.$14.73-4.84%$1.6B
ANIPANI Pharmaceuticals Inc.$70.89-0.77%$1.6B
RAREUltragenyx Pharmaceutical Inc.$15.90-1.12%$1.6B
SRPTSarepta Therapeutics Inc. Common Stock (DE)$15.13-5.85%$1.6B
KRSAKorsana Biosciences Inc.$32.68+3.25%$1.5B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier